Analyst Price Targets — DLB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 19, 2025 9:26 am | Steve Frankel | Rosenblatt Securities | $85.00 | $64.96 | StreetInsider | Dolby Laboratories (DLB) PT Lowered to $85 at Rosenblatt |
| September 4, 2025 8:24 pm | Vikram Kesavabhotla | Robert W. Baird | $74.00 | $72.79 | TheFly | Dolby initiated with a Neutral at Baird |
| May 15, 2025 1:43 pm | Ivan Feinseth | Tigress Financial | $112.00 | $77.24 | TheFly | Dolby reinstated with a Buy at Tigress Financial |
| February 3, 2023 8:26 am | — | Rosenblatt Securities | $90.00 | $82.67 | Benzinga | Rosenblatt Maintains Buy on Dolby Laboratories, Raises Price Target to $90 |
Latest News for DLB
SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) fiscal year 2026 after the close of regular trading on Thursday, July 30, 2026. Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 fiscal year 2026 financial results for Dolby…
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and…
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -
Amid cautious discretionary spending and macro troubles, investments in cutting-edge solutions are likely to aid Zacks Audio Video Production industry participants like SONY, DLB and SONO.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DLB.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.